[Indications for the use of tactivin in the combined treatment of phlegmons of the maxillofacial area].
The effects of subcutaneous and endolymphatic tactivin (in doses of 1 ml of 0.01% solution daily for 7 days) on clinical and immunological parameters were studied in patients with acute inflammations in the maxillofacial area, running a normo-, hypo-, and hyperergic course. Tactivin accelerated the arrest of inflammatory process and improved the patients' status, particularly so in cases with the hypo- and hyperergic inflammations. The key role in the mechanism of the drug action is played by increase of the immunoregulatory index, which reflects the increasing resistance of the body.
Drobyshev
V Iu
VIu
Volozhin
A I
AI
Agapov
V S
VS
Sashkina
T I
TI
D000208:Acute Disease; D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D001402:B-Lymphocytes / Q000187:drug effects / Q000276:immunology; D002481:Cellulitis / Q000188:drug therapy* / Q000276:immunology; D003131:Combined Modality Therapy; D004341:Drug Evaluation; D005145:Face; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D007571:Jaw Diseases / Q000188:drug therapy* / Q000276:immunology; D010455:Peptides / Q000008:administration & dosage*; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D013949:Thymus Extracts / Q000008:administration & dosage*
D000276:Adjuvants, Immunologic; D010455:Peptides; D013949:Thymus Extracts; C036191:T-activin